4,965 Shares in Zoetis Inc. $ZTS Purchased by Bridgefront Capital LLC

Bridgefront Capital LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,965 shares of the company’s stock, valued at approximately $726,000.

Several other institutional investors have also recently bought and sold shares of the company. Halbert Hargrove Global Advisors LLC grew its stake in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. Financial Consulate Inc. acquired a new stake in shares of Zoetis in the third quarter valued at approximately $39,000. SJS Investment Consulting Inc. lifted its position in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after purchasing an additional 257 shares in the last quarter. TruNorth Capital Management LLC acquired a new position in Zoetis during the third quarter worth $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in Zoetis during the third quarter worth $46,000. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent research reports. Bank of America lifted their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Barclays began coverage on Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. Six analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Zoetis has an average rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Shares of ZTS stock opened at $115.62 on Monday. The stock has a market cap of $48.81 billion, a P/E ratio of 19.21, a P/E/G ratio of 1.76 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The company has a fifty day moving average price of $125.34 and a two-hundred day moving average price of $131.58. Zoetis Inc. has a one year low of $114.47 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.